OAC
PRLD icon

OMERS Administration Corp’s Prelude Therapeutics PRLD Stock Holding History

OMERS Administration Corp’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Sell
32,700
-40,300
-55% -$106K ﹤0.01% 1002
2025
Q4 		$212K Buy
+73,000
New +$123K ﹤0.01% 901

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OMERS Administration Corp's PRLD Position: Q1 2026 in Review

OMERS Administration Corp reduced its Prelude Therapeutics (PRLD) stake by 55% in Q1 2026, selling an estimated $106K and leaving 32,700 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

OMERS Administration Corp first reported a position in PRLD in Q4 2025 and has held it in 2 quarters since. The position peaked at $212K in Q4 2025. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • OMERS Administration Corp held 32,700 shares of Prelude Therapeutics worth $112K as of Q1 2026.
  • OMERS Administration Corp sold 40,300 Prelude Therapeutics shares in Q1 2026, an estimated $106K.
  • Prelude Therapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #1002 holding.
  • OMERS Administration Corp first reported a position in Prelude Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's Prelude Therapeutics position peaked at $212K in Q4 2025.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.